Addus HomeCare Corporation Stock News

Addus Homecare (NASDAQ:ADUS) is scheduled to be announcing its earnings results after the market closes on Monday, May 4th. Analysts expect the company to announce earnings of $0.56 per share for the

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Community Health (CYH) today and set a price target of $7.00. The company's shares

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Community Health ( CYH – Research Report ) today and set a price target of $7.00 . The company’s shares closed last Friday at $2.8

After Bernstein and Credit Suisse gave Cigna (NYSE: CI) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst

After Bernstein and Credit Suisse gave Cigna (NYSE: CI ) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Michael Wiederhorn maintained a Buy rating on Ci

Columbus Circle Investors lifted its position in Addus Homecare Co. (NASDAQ:ADUS) by 40.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio

Addus Homecare Co. (NASDAQ:ADUS) traded up 5.6% during mid-day trading on Wednesday . The stock traded as high as $83.70 and last traded at $83.08, 149,816 shares changed hands during mid-day trading.

Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release preliminary earnings for the first quarter ended March 31, 2020, on Monday, May 4, 2

In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Humana (HUM), with a price target of $400.00. The company's

In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Humana (HUM – Research Report), with

Aufstockung der Mittel für Fraueneinrichtungen auf 210 Millionen Euro zur Krisenbewältigung sofort notwendig

In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Community Health (CYH), with a price target of $8.00. The

In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Community Health ( CYH – Research Report ), with a price target of $8.00 . The company’s shares close

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE) yesterday and set a price target of $535.00. The company's shares closed

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE – Research Report) yesterday and set a price target